Warm Autoimmune Hemolytic Anaemia Treatment Market Report 2023 | R&D Consistency Drives Sector Growth

The global Warm Autoimmune Hemolytic Anaemia (WAIHA) Treatment Market was worth US$ 582.99 million in 2022 and is predicted to be worth US$ 1598 million by 2033, growing at a CAGR of 9.6% from 2023 to 2033. The increasing prevalence of autoimmune hemolytic anaemia (WAIHA), rising awareness and diagnosis rates, and the development of new and effective treatment options all contribute to the growth of the autoimmune hemolytic anaemia (WAIHA) treatment market. From 2018 to 2022, the market for autoimmune hemolytic anaemia (WAIHA) treatment grew at a CAGR of 5.4%.

The medical procedures used to manage the symptoms and underlying causes of warm autoimmune hemolytic anaemia (WAIHA) are referred to as WAIHA treatment. WAIHA is an autoimmune illness in which the immune system assaults and destroys red blood cells by mistake, resulting in anaemia.

WAIHA is typically treated with immunosuppressive medicines such as corticosteroids, which suppress the immune system and minimise red blood cell damage. Immunomodulatory medications, such as rituximab or cyclophosphamide, that target particular components of the immune system to suppress the autoimmune response, may also be used as therapies.

Blood transfusions may be performed in some circumstances to replace destroyed red blood cells and alleviate symptoms. In severe situations, a splenectomy (surgical removal of the spleen) may be required to decrease red blood cell damage.

Market Competition

Key players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Sanofi, Incyte Corporation, Teva Pharmaceutical Industries Ltd, Momenta Pharmaceuticals, Alexion Pharmaceuticals, Inc., Immunovant, F. Hoffmann-La Roche Ltd

Read More@ https://www.futuremarketinsights.com/reports/warm-autoimmune-hemolytic-anemia-treatment-market

Key Segments Profiled in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Survey

Drug Class:

  • Fostamatinib
  • Sutimlimab
  • Parsaclisib
  • Rilzabrutinib
  • Isatuximab

Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Comments

Post a Comment

Popular posts from this blog

Empowering Diabetics | A Comprehensive Analysis of the Continuous Glucose Monitoring Device Market

Image
According to Future Market Insights' recently released Continuous Glucose Monitoring Device Market Analysis report, global sales of Continuous Glucose Monitoring Device Market in 2022 will be US$ 4.9 Billion. The market is expected to be valued US$ 16.8 billion by 2033, with a CAGR of 11.9% from 2023 to 2033. Market growth is predicted to be driven by an increase in the older population as well as a high prevalence of diabetes. The International Diabetes Federation predicts that the global diabetic population will reach 642 million by 2040. As a result, by 2040, one out of every 10 people would have diabetes, demonstrating the seriousness of the epidemic. Diabetes treatment and management are consequently projected to be a top priority for healthcare administrations and stakeholders around the world. Diabetes cases are predicted to increase, boosting market growth and the potential for continuous glucose monitoring systems, attracting and motivating various industry actors to prod...
Read more

Global Medical face shield Market Insights and Outlook 2022-2032

Image
Medical face shield can become as ubiquitous as masks, as new findings on the airborne spread of Covid-19 influence behavior and guidelines. According to a latest study by Future Market Insights,  Medical Face Shields Market  will grow at over 11% CAGR through 2030. Medical face shields have proven to be an effective first-line defence against airborne diseases such as Zika, SARS, Ebola, flu, and now Covid-19. As a result, increased adoption of medical face shields, and thus increased production, is expected to drive the market during the forecast period. The IDSA (Infectious Diseases Society of America) has included the use of PPE (Personal Protective Equipment) such as face shields and masks in its recommendations. Though masks have been widely used throughout the world, their effectiveness is not widely known. The possibility of cloth masks providing marginal virus protection due to potential moisture retention, poor filtration, and re-use cannot be ruled out. Face ...
Read more

Cognitive Diagnostics Market Projected to Reach Unprecedented Growth by 2033

Image
As per Future Market Insights latest industry analysis, the valuation for the global  Cognitive Diagnostics market sales  is estimated to reach US$ 110.2 Billion in 2023 and is projected to exhibit a CAGR of 8.0% over the forecast period, with an estimated valuation of US$ 238.3 Billion by 2033. Several causes of brain problems or cognitive disorders include closed head injuries, contact with neurotoxins (toxic substances), genetics, infections, strokes, and tumours. Depending on the area of the brain that is impacted, a person may have a certain form of cognitive problem. Communication issues could result from, for instance, a tumour in the speech cisterns of the brain. In another illustration, a brain infection that affects the motor recentres would cause problems with movement. Ageing is also a factor in the development of cognitive problems. Cognitive diagnostics increasingly use digital health technologies like wearables and smartphone apps. These tools can monitor a pati...
Read more